Lung cancer (CP) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of new cases of CP for 2019 was 29,503 cases. CP remains the leading cause of cancer death in Spain in both sexes, with an overall five-year survival of 13%, which decreases to 1% in the metastatic stage. Non-small cell lung cancer (PCNM) accounts for approximately 80% - 90% of all CPs and is classified according to histology into adenocarcinoma (≈ 40%), large cell carcinoma (15%), and cell carcinoma. squamous or epidermoid cells (≈ 25 - 30%). Currently, pharmacological treatment of action-free non-target CPNM is based on the administration of immunotherapy, immunotherapy and chemotherapy regimens, and platinum-based chemotherapy doublets. Subsequently, treatment is based on the use of a third-generation cytostatic drug alone or, in the case of non-scaly histology, combined with an antiangiogenic agent.
Metastatic non-microcytic lung cancer; CPNM; Nintedanib; Health Results
Programa d'Harmonització Farmacoterapèutica. Tractament del CPNM metastàtic amb nintedanib en segona línia: informe d'avaluació de resultats. Barcelona: Servei Català de la Salut; 2021.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/6352
This item appears in following collections
The following license files are associated with this item: